Bridging the U.S. - E.U. Gap - The New Commercialization Trend in the Medical Device Sector
From clinical work to commercialization, the non-U.S. market opportunity may lend itself to obtaining further rounds of financing or going public successfully.
Portland, OR, October 04, 2012 --(PR.com)-- More than 7,000 entrepreneurs, venture capitalists and industry players will be in Orange County when the OCTANe startup accelerator will host its seventh annual Medical Device & Investor Forum (MDIF) at the Hyatt Regency in Irvine, California. There will be presentations and panel discussions hosted by leading industry experts. Haio Fauser, Founder and Principal at acroMIS Global MedTech, will share his perspective on the panel "The Path to Successful Commercialization in Europe" on Thursday, October 11, 2012 from 11:00 – 12:00.
One of the unique features of the U.S. ecosystem is the collaboration between academia, industry, and healthcare professionals. But even in this well-established industry, there are new opportunities to be explored. U.S. medical device companies are turning to Europe as an initial commercialization market for new technology. European clinical studies, and cost studies are instrumental in generating the published data which hospitals, MDs, providers and payers demand.
Going to the European Union (EU) might be a good alternative in the current market environment. The panel will review critical success factors, and discuss opportunities for earlier-stage medical device companies to explore commercialization and sales launch programs. Markets in the EU often are more receptive to early start-up stage companies, even if a company hasn’t yet achieved FDA clearance.
Haio, who recently linked with Medeuronet, comments, “I expect the U.S. medical device industry to remain highly competitive globally, due to the national characteristics that facilitate bringing innovative technologies to market. The U.S., E.U., and Japan are extremely large and lucrative medical device markets. And the demand for U.S. innovations continues to grow due to aging populations in our major markets, and the harmonization of global standards and regulatory requirements.”
The EU has historically been the largest regional export market for U.S. medical devices and is expected to continue to be fertile ground for exports of U.S.-made high-technology products due to high per capita income in EU countries, a favorable regulatory environment and an aging population. Significant individual markets in the EU for U.S. medical device companies include Germany, France, and the UK.
About acroMIS Global MedTech: acroMIS LLC is an entrepreneurial service provider company managed by Haio Fauser. Haio is passionately committed to commercializing innovative medical technologies so that providers can use cutting edge devices and at the same time deliver the highest quality of care to patients. He has a demonstrated track record in upstream & downstream commercialization, refining of product launch plans, due diligence for global commercialization, insights for proof and acceptance, and also in go-to-market planning for commercial launches and expansions. Haio holds a German B.A. in International Commerce, and a U.S. MBA. He speaks English, German, and Japanese.
One of the unique features of the U.S. ecosystem is the collaboration between academia, industry, and healthcare professionals. But even in this well-established industry, there are new opportunities to be explored. U.S. medical device companies are turning to Europe as an initial commercialization market for new technology. European clinical studies, and cost studies are instrumental in generating the published data which hospitals, MDs, providers and payers demand.
Going to the European Union (EU) might be a good alternative in the current market environment. The panel will review critical success factors, and discuss opportunities for earlier-stage medical device companies to explore commercialization and sales launch programs. Markets in the EU often are more receptive to early start-up stage companies, even if a company hasn’t yet achieved FDA clearance.
Haio, who recently linked with Medeuronet, comments, “I expect the U.S. medical device industry to remain highly competitive globally, due to the national characteristics that facilitate bringing innovative technologies to market. The U.S., E.U., and Japan are extremely large and lucrative medical device markets. And the demand for U.S. innovations continues to grow due to aging populations in our major markets, and the harmonization of global standards and regulatory requirements.”
The EU has historically been the largest regional export market for U.S. medical devices and is expected to continue to be fertile ground for exports of U.S.-made high-technology products due to high per capita income in EU countries, a favorable regulatory environment and an aging population. Significant individual markets in the EU for U.S. medical device companies include Germany, France, and the UK.
About acroMIS Global MedTech: acroMIS LLC is an entrepreneurial service provider company managed by Haio Fauser. Haio is passionately committed to commercializing innovative medical technologies so that providers can use cutting edge devices and at the same time deliver the highest quality of care to patients. He has a demonstrated track record in upstream & downstream commercialization, refining of product launch plans, due diligence for global commercialization, insights for proof and acceptance, and also in go-to-market planning for commercial launches and expansions. Haio holds a German B.A. in International Commerce, and a U.S. MBA. He speaks English, German, and Japanese.
Contact
acroMIS Global MedTech
Haio Fauser
(650) 336-8641
www.acromis.com
Haio Fauser
(650) 336-8641
www.acromis.com
Contact
Categories